Cancer Epigenomics: New Clinical Opportunities and Challenges

Dear colleagues,

Genome-wide epigenetic alterations are now a well-established hallmark of cancer, and recent years have witnessed the advent of high-throughput technologies applied to epigenomics. In particular, the development of WG-BS sequencing, ChIP-seq, FAIRE-seq, ATAC-inspired methodologies (ATAC-seq, ATAC-me) and RNA-seq, among others, has enabled a growing body of research aimed at characterizing epigenetic changes at the global scale. These such studies have begun to generate useful datasets along with new tools and strategies for cancer research. Furthermore, the reversible nature of epigenetic changes opens up the possibility of partially restoring the abnormal cancer epigenome to its healthy state, thus representing an attractive strategy for cancer therapy.

In this Special Issue dedicated to cancer epigenomics, we invite original experimental and clinical studies as well as reviews of the plethora of altered epigenetic mechanisms during tumorigenesis as seen through the -omics prism. We will address epigenomic studies and integrative analysis of epigenomic data across different tumor types, with a special focus on clinical translation under the form of novel diagnostic biomarkers as well as new opportunities for cancer patient screening, stratification, and follow-up. We will also discuss challenges that need to be overcome in future to expedite translation of these findings into clinical oncology.

Prof. Dr. Mario Fdez. Fraga
Dr. Virginia López Martínez
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• epigenetics
• epigenome
• DNA methylation
• chromatin
• histone posttranslational modifications
• microRNAs
• bioinformatics
• omics analyses